Literature DB >> 28371016

Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature.

Jaya M Telang1, Brian R Lane2, Michael L Cher3, David C Miller1, James M Dupree1.   

Abstract

Active surveillance (AS) is an increasingly prevalent treatment choice for low grade prostate cancer. Eligibility criteria for AS are varied and it is unclear if family history of prostate cancer should be used as an exclusion criterion when considering men for AS. To determine whether family history plays a significant role in the progression of prostate cancer for men undergoing active surveillance, PubMed searches of 'family history and prostate cancer', 'family history and prostate cancer progression' and 'factors of prostate cancer progression' were used to identify research publications about the relationship between family history and prostate cancer progression. These searches generated 536 papers that were screened and reviewed. Six publications were ultimately included in this analysis. Review of the six publications suggests that family history does not increase the risk of prostate cancer progression, whilst a subgroup analysis in one study found that family history increases the risk of prostate cancer progression only in African-Americans. A family history of prostate cancer does not appear to increase a patient's risk of having more aggressive prostate cancer and is therefore unlikely to be an important factor in determining eligibility for AS. Further studies are needed to better understand the relationship between race, family history, and eligibility for AS.
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; active surveillance; family history

Mesh:

Substances:

Year:  2017        PMID: 28371016     DOI: 10.1111/bju.13862

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

Review 1.  [Familial prostate cancer and genetic predisposition].

Authors:  V H Meissner; M Jahnen; K Herkommer
Journal:  Urologe A       Date:  2021-03-15       Impact factor: 0.639

2.  Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies.

Authors:  Daniel N Costa; Qi Cai; Yin Xi; Debora Z Recchimuzzi; Naveen Subramanian; Aditya Bagrodia; Neil M Rofsky; Claus G Roehrborn; Brad Hornberger; Rajal B Shah; Kenneth Goldberg; Alberto Diaz de Leon; Ivan Pedrosa
Journal:  Radiol Imaging Cancer       Date:  2021-03-05

3.  Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.

Authors:  Ghalib A Jibara; Marlon Perera; Emily A Vertosick; Daniel D Sjoberg; Andrew Vickers; Peter T Scardino; James A Eastham; Vincent P Laudone; Karim Touijer; Xin Lin; Maria I Carlo; Behfar Ehdaie
Journal:  J Urol       Date:  2022-04-04       Impact factor: 7.600

4.  Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.

Authors:  Anirudh Tomer; Dimitris Rizopoulos; Daan Nieboer; Frank-Jan Drost; Monique J Roobol; Ewout W Steyerberg
Journal:  Med Decis Making       Date:  2019-07-18       Impact factor: 2.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.